Literature DB >> 31732189

The effect of Clinical Practice Guidelines on prescribing practice in mental health: A systematic review.

Tony Nguyen1, Natalie Seiler1, Ellie Brown1, Brian O'Donoghue2.   

Abstract

Clinical Practice Guidelines are succinct evidence-based recommendations and in psychiatry, exist to advise on psychotropic prescribing to effectively treat mental health conditions whilst minimising medication adverse effects. Implementation of psychiatric guidelines have, in the past, demonstrated little and transient impact on clinical practice. How effective prescribing guidelines are in aligning practice with evidence currently is unknown and this systematic review aimed to investigate said efficacy. Literature searches were performed on MEDLINE, EMBASE, and CINAHL up to September 2019 and articles were selected by two reviewers independently with discrepancies resolved by a third reviewer. The review identified 18 eligible articles pertaining to the following conditions: depressive disorders, psychotic disorders, post-traumatic stress disorder, anxiety disorders, bipolar affective disorder, attention deficit/hyperactivity disorder, borderline personality disorder, and opiate addiction with depression guidelines being the most frequently evaluated. Seven studies revealed guidelines effected no change in psychotropic prescribing. The remaining studies illustrated that even when practice was changed, the effect was generally small, emphasising the need to change guideline development and implementation, taking into account obstacles or opportunities specific to psychotropic pharmacotherapy.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Evidence-based practice; Mental health; Physicians; Practice guideline; Practice guidelines as topic; Practice patterns; Psychotropic drugs

Year:  2019        PMID: 31732189     DOI: 10.1016/j.psychres.2019.112671

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  6 in total

1.  Strategies to prevent long-term opioid use following trauma: a Canadian practice survey.

Authors:  Mélanie Bérubé; Caroline Côté; Lynne Moore; Alexis F Turgeon; Étienne L Belzile; Andréane Richard-Denis; Craig M Dale; Gregory Berry; Manon Choinière; Gabrielle M Pagé; Line Guénette; Sébastien Dupuis; Lorraine Tremblay; Valérie Turcotte; Marc-Olivier Martel; Claude-Édouard Chatillon; Kadija Perreault; François Lauzier
Journal:  Can J Anaesth       Date:  2022-09-26       Impact factor: 6.713

2.  Trends in Brazilian market of antidepressants: A five-year dataset analysis.

Authors:  Rogério Hoefler; Taís Freire Galvão; Inês Ribeiro-Vaz; Marcus Tolentino Silva
Journal:  Front Pharmacol       Date:  2022-10-04       Impact factor: 5.988

3.  Twenty-Year Trends in the Psychopharmacological Treatment of Outpatients with Borderline Personality Disorder: A Cross-Sectional Naturalistic Study in Spain.

Authors:  Juan C Pascual; Ana Martín-Blanco; Joaquim Soler
Journal:  CNS Drugs       Date:  2021-08-09       Impact factor: 5.749

4.  Minding metabolism: targeted interventions to improve cardio-metabolic monitoring across early and chronic psychosis.

Authors:  John R Kelly; Priyola Gounden; Aoibheann McLoughlin; Zahra Legris; Therese O'Carroll; Roisin McCafferty; Liliana Marques; Maeve Haran; Richard Farrelly; Karen Loughrey; Gráinne Flynn; Aiden Corvin; Catherine Dolan
Journal:  Ir J Med Sci       Date:  2021-03-08       Impact factor: 1.568

5.  Improvements in the degree of understanding the treatment guidelines for schizophrenia and major depressive disorder in a nationwide dissemination and implementation study.

Authors:  Shusuke Numata; Masahito Nakataki; Naomi Hasegawa; Yoshikazu Takaesu; Masahiro Takeshima; Toshiaki Onitsuka; Toshinori Nakamura; Reon Edagawa; Hiroaki Edo; Kenichiro Miura; Junya Matsumoto; Norio Yasui-Furukori; Taishiro Kishimoto; Hikaru Hori; Takashi Tsuboi; Yuka Yasuda; Ryuji Furihata; Hiroyuki Muraoka; Shinichiro Ochi; Tatsuya Nagasawa; Yoshitaka Kyou; Atsunobu Murata; Eiichi Katsumoto; Kazutaka Ohi; Akitoyo Hishimoto; Ken Inada; Koichiro Watanabe; Ryota Hashimoto
Journal:  Neuropsychopharmacol Rep       Date:  2021-03-11

6.  Pharmacological treatment algorithms for the acute phase, agitation, and maintenance phase of first-episode schizophrenia: Japanese Society of Clinical Neuropsychopharmacology treatment algorithms.

Authors:  Hiroyoshi Takeuchi; Yoshiteru Takekita; Hikaru Hori; Kazuto Oya; Itaru Miura; Naoki Hashimoto; Norio Yasui-Furukori
Journal:  Hum Psychopharmacol       Date:  2021-07-09       Impact factor: 1.672

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.